Physician profile
Nathaniel Lampley
NPI 1558066779
$957.08
in general payments reported to CMS, 2019-2025
13 companies · $565 in 2025
The $565 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $392 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $221.28 | 2025 | Tremfya |
| Abbvie INC. | $140.65 | 2024 | |
| Janssen Scientific Affairs, LLC | $140.52 | 2025 | Tremfya |
| Dermavant Sciences, INC. | $90.76 | 2024 | Vtama |
| Amgen INC. | $65.72 | 2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.97 | 2024 | Spevigo |
| Almirall LLC | $50.00 | 2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $45.78 | 2024-2025 | Zoryve |
| Genzyme Corporation | $45.73 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $33.46 | 2024 | |
| Incyte Corporation | $24.82 | 2025 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $21.83 | 2025 | Saphnelo |
| Kyowa Kirin, INC. | $17.56 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Lampley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.